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Preadipocytes in inﬂammatory bowel disease (IBD) have
acquired, differential disease-dependent characteristics that
lead to changes in the release of inﬂammation-associated
mediators after substance P (SP) treatment; interleukin 17
(IL-17) is the most consistently regulated mediator in iso-
lated human mesenteric preadipocytes.
BACKGROUND & AIMS: Substance P (SP) neurokinin-1 re-
ceptors (NK-1Rs) are expressed in mesenteric preadipocytes,
and SP binding activates proinﬂammatory signaling in these
cells. We evaluated the expression levels of SP (Tac-1), NK-1R
(Tacr-1), and NK-2R (Tacr-2) mRNA in preadipocytes isolated
from patients with inﬂammatory bowel disease (IBD) and
examined their responsiveness to SP compared with control
human mesenteric preadipocytes. We investigated the effect of
the neuropeptide SP on cytokine expression in preadipocytes
of IBD versus control patients and evaluated the potential
effects of these cells on IBD pathophysiology via SP-NK-R
interactions.
METHODS: Mesenteric fat was collected from control, ulcera-
tive colitis (UC) and Crohn’s disease patients (n ¼ 10–11 per
group). Preadipocytes were isolated, expanded in culture, and
exposed to substance P. Colon biopsy samples were obtained
from control and IBD patients.
RESULTS: Tacr-1 and -2 mRNA were increased in IBD pre-
adipocytes compared with controls, but Tac-1 mRNA was
increased only in UC preadipocytes. SP differentially regulated
the expression of inﬂammatory mediators in IBD preadipocytes
compared with controls. Disease-dependent responses to SP
were also observed between Crohn’s disease and UC pre-
adipocytes. Interleukin 17A (IL-17A) mRNA expression and
release increased after SP treatment in both Crohn’s disease
and UC preadipocytes; IL-17RA mRNA increased in colon bi-
opsies samples from IBD patients.
CONCLUSIONS: Preadipocyte SP-NK-1R interactions during IBD
may participate in IBD pathophysiology. The ability of human
preadipocytes to release IL-17A in response to SP together withincreased IL-17A receptors in the IBD colon suggests that a fat-
colonic mucosa inﬂammatory loop may be active during IBD.
(Cell Mol Gastroenterol Hepatol 2015;1:420–432; http://
dx.doi.org/10.1016/j.jcmgh.2015.03.003)
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ubstance P (SP) is an endecapeptide1 member ofSthe tachykinin family of peptides and a product of
the preprotachykinin-A (Tac1) gene.2 SP signals via
binding to three G-protein–coupled neurokinin receptors
(NK-1R-2R-3R), with highest afﬁnity for NK-1R.2 SP is
expressed in numerous tissues and organs, including the
gastrointestinal tract.2,3 SP is also expressed in cells of
the immune system, and it functions both as a neuro-
transmitter and an immune modulator in many disease
states, including several intestinal diseases with an in-
ﬂammatory phenotype.2,4
Inﬂammatory bowel disease (IBD), which includes ul-
cerative colitis (UC) and Crohn’s disease, comprises complex
diseases of unknown etiology. The pathophysiology of these
diseases involves complex interactions between genetic,
microbial, and immune factors.5 Our group and others have
shown that SP and NK-1R have a role in the pathophysiology
of intestinal inﬂammation, including IBD.6–8 NK-1R expres-
sion is increased in the intestinal mucosa of mice with
July 2015 SP, Adipocytes, and IBD 421intestinal inﬂammation9 as well as IBD patients.7,10,11
Studies employing NK-1R knockout mice12,13 and SP re-
ceptor antagonists14–17 show that SP, via NK-1R, plays a
dual role in the development of colitis. SP acts as a proin-
ﬂammatory peptide in acute intestinal inﬂammation but
also enhances proliferation and mucosal healing during
chronic colitis13,16,18,19 by activating distinct protective
signaling pathways.14,19,20 The mechanism involved in the
proinﬂammatory NK-1R–associated responses includes in-
teractions of SP with NK-1R on epithelial and inﬂammatory
cells10,21,22 and the release of cytokines17,23,24 that modulate
colitis and colitis-associated motility3 primarily by acti-
vating pathways dependent on nuclear factor kB (NF-kB).6
A potential role for adipose tissue in IBD pathophysi-
ology is suggested by clinical studies associating increased
body mass index (BMI) with the development of active
Crohn’s disease and the requirement of patients for hospi-
talization.25 Fat accumulation surrounding the inﬂamed in-
testine (“creeping fat”) during Crohn’s disease represents a
hallmark of the disease.26,27 Histologic examination of the
mesenteric fat of patients with creeping fat demonstrated
inﬂammatory changes26 and alterations of adipokine levels
in the circulation of IBD patients.28 These data combined
with the emergence of fat as an endocrine organ29 suggest
a role of intra-abdominal fat in IBD pathophysiology. Pre-
viously, we demonstrated the presence of NK-1R in human
mesenteric preadipocytes30 along with activation of in-
ﬂammatory,30 antiapoptotic,31 and metabolic32,33 pathways
after SP treatment. We also reproduced the creeping fat
phenotype in the intracolonic trinitrobenzylsulfonic acid
(TNBS) mouse colitis model that was associated with
increased proinﬂammatory cytokine expression in these
depots.30 However, modulation of expression of SP and NK-
1R in adipose tissue during IBD has never been examined,
and the responsiveness of IBD preadipocytes to SP has not
been determined.
Here, we compared for the ﬁrst time the effects of SP
treatment on cytokine production in human mesenteric
preadipocytes isolated from a substantial number of control,
UC, and Crohn’s disease patients. In these cells, we also
compared the levels of expression of the Tac1 and NK-1R,
NK-2R, and NK-3R genes. Initially, we demonstrate differ-
ential cytokine release from preadipocytes isolated from
IBD patients compared with controls. We show that human
mesenteric preadipocytes isolated from UC and Crohn’s
disease patients release express higher levels of NK-1R and
NK-2R but not NK-3R. We also found that human mesenteric
preadipocytes express Tac-1 mRNA, whose expression was
elevated in UC but not Crohn’s disease preadipocytes.
Further, we present evidence that UC and Crohn’s disease
preadipocytes display differential responses after treatment
with SP compared with cells from control patients. Our data
also demonstrate IBD-disease dependent changes in SP-
induced inﬂammatory stimulation of human pre-
adipocytes, including increased interleukin 17A (IL-17A)
transcription, while interleukin 17 receptor A (IL-17RA)
mRNA expression is higher in colonic biopsy samples of
both UC and Crohn’s disease patients compared with
controls.Materials and Methods
Patients
Mesenteric fat tissues from male and female IBD (11 UC,
11 Crohn’s disease) and non-IBD patients (adenocarcinoma
surgery, other gastrointestinal complications, or vascular
surgery, n ¼ 10) were used. The group of control patients
was either of Hispanic or (mainly) of Caucasian descent,
mixed both males and females, and had an average BMI of
26.86. Their pathologies included four with adenocarci-
noma, two with polyposis coli, one with Whipple disease,
one with diverticulitis, one with idiopathic motility disorder,
and one with tubular adenoma. The UC and Crohn’s disease
patients were also a mixed population of men and women
with an average BMI of 27.23 and 24.12, respectively. The
protocol was approved by the UCLA institutional review
board for human research (11-001527-AM-00003).
All patients fasted for at least 10 hours before surgery
and provided informed consent. Tissues from Cedar’s Sinai
were obtained after informed consent in accordance with
procedures established by the Cedars-Sinai institutional
review board (3358 and 23705). Tissues from Chicago were
obtained in accordance with procedures established by the
University of Chicago institutional review board (IRB
12960). Colon biopsy samples were collected from patients
undergoing colonoscopy for colon cancer screening or IBD
disease activity monitoring. The samples were obtained,
immediately frozen, and used for RNA isolation.Isolation and Cell Culture of Human
Preadipocytes
We minced 2–5 g of mesenteric fat tissue from each
patient into pieces. The samples were then placed in 50-mL
tubes containing collagenase solution (1 mg/1 mL of
phosphate-buffered saline, 3 mL solution/1 g tissue) and
minced to a ﬁne consistency. After vortexing, the tubes were
placed in a 37C shaking water bath (100 rpm) for 40 mi-
nutes. The solution was vortexed and ﬁltered through a
sterile 100-mm nylon mesh (Fisher Scientiﬁc, Hampton, NH).
The homogenates were centrifuged at 1000 rpm for 10 mi-
nutes. The pellet was then resuspended in 10 mL
of erythrocyte lysis buffer (cat. no. A1049201, GIBCO/Invi-
trogen, Grand Island, NY), placed in a 37C shaking water
bath for 5 minutes at 100 rpm, and then centrifuged at 1000
rpm for 10 minutes. The pellet was resuspended in 10 mL of
plating medium (Dulbecco’s modiﬁed Eagle medium, 0.1
mM penicillin, 0.06 mM streptomycin, 10% HI-fetal bovine
serum, pH 7.4), vortexed, plated onto 100-mm dishes, and
incubated at 37C.Culture of Human Preadipocytes
After 20 hours, the cells were washed three times with
10 mL of phosphate-buffered saline, and 1 mL of trypsin
solution (Invitrogen, Carlsbad, CA) was added. The trypsin
was inactivated with 5 mL of plating medium, and the cells
were centrifuged at 1000 rpm for 10 minutes. After resus-
pension in plating medium, the cells were plated at 5  104
cells/cm2 in plating medium and incubated at 37C until
422 Sideri et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4conﬂuence. Previous studies have demonstrated that this
isolation procedure yields >99% pure preadipocyte pop-
ulations.34 The cells were then subcultured three or four
times to ensure the removal of macrophages. No ADAM8,
F4/80, or macrophage inﬂammatory protein-1a mRNA
(markers of macrophages) were detected by an Affymetrix
array (Affymetrix, Santa Clara, CA) analysis of human
mesenteric preadipocytes prepared using this protocol.
Preadipocytes at passages three to four were then exposed
to 107 M SP for 8 hours in 3 mL of human maintenance
medium (Dulbecco’s modiﬁed Eagle medium/Ham’s F-12
medium with 23 mM HEPES, 25 mM NaHCO3, 0.1 mM
penicillin, 0.06 mM streptomycin, 10 mg/L transferin,
0.3 mM biotin, and 2 mM L-glutamine). The medium and
the RNA of the cells were collected for analysis. Protein
lysates were also collected from preadipocytes in plating
medium.
Real-Time Polymerase Chain Reaction
The RNA was isolated from human mesenteric pre-
adipocytes and colon biopsy samples using the TRIzol
method. We reverse-transcribed 1 mg of RNA into cDNA
as previously described elsewhere33 and incubated with
dual ﬂuorogenic probes (Applied Biosystems, Foster
City, CA).
The levels of the target mRNA were quantiﬁed using a
ﬂuorogenic 50-nuclease polymerase chain reaction (PCR)
assay using a 7500 Fast Real-Time PCR sequence detection
system according to manufacturers instructions (Applied
Biosystems). Cycle conditions were subject to change for
higher efﬁciency as different targets required. The primers
used were Hs00243225_m1 (Tac1), Hs00185530_m1
(Tacr1), Hs00169052_m1 (Tacr2), Hs00357277_m1
(Tacr3), Hs01064648_m1 (IL-17RA), Hs00994305_m1
(IL-17RC), and for normalization Hs03928990_g1 (Human
Eukaryotic 18S rRNA) (all from Applied Biosystems).
Western Immunoblot Analysis
Proteins were collected from human mesenteric pre-
adipocytes of control, UC, and Crohn’s disease patients
(n ¼ 4 per group) in RIPA TRITON X100 (BP-116TX;
Boston BioProducts, Ashland, MA) with protease and
phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). We
loaded 30 mg of protein on a 10% polyacrylamide gel and
electrophoresed it for 1.5 hours. The proteins were
transferred on polyvinylidene ﬂuoride membranes, and the
membranes were blocked for 1 hour at room temperature
in LI-COR blocking buffer (LI-COR Biosciences, Lincoln,
NE). The membranes were blotted with a rabbit NK-1R
primary antibody at a dilution of 1:100 overnight at
room temperature (sc-15323; Santa Cruz Biotechnology,
Santa Cruz, CA). Secondary goat anti-rabbit antibody
(1:15,000, cat. no. 926-32211; LI-COR Biosciences) was
added for 1 hour at room temperature. Loading was
normalized using a mouse b-actin primary antibody
(1:1000, cat. no. sc-81178; Santa Cruz Biotechnology) and
a goat anti-mouse secondary antibody (1:15,000, cat. no.
926-68170; LI-COR Biosciences). Bands were visualizedand quantiﬁed using the Odyssey IR Imaging System
(LI-COR Biosciences).
mRNA Multiplex Analysis
Total RNA was isolated as described earlier, and
inﬂammation-related gene expression was analyzed using
the 42-plex FlexScript LDA inﬂammatory panels 3 and 4
(Luminex, Austin, TX). We loaded 20 ng of total RNA in each
well, and then we performed the treatments described in
the company’s manual (FlexScript LDA). The plate was run
using Bio-Plex 3D suspension array system (Bio-Rad Labo-
ratories, Hercules, CA). In addition to the total RNA con-
centration, the data were normalized to endogenous
controls (GAPDH, B2M, b-actin) included within the gene
panels.
Multiplex Cytokine and Phosphoprotein
Immunoassays
Human mesenteric preadipocytes were isolated and
plated as described previously, and media were collected at
the end of the 8-hour exposure to SP. Cytokine concentra-
tions in human preadipocyte media were determined using
the Bio-Plex ProTM Human Cytokine 27-Plex, Group I, with
magnetic beads (Bio-Rad Laboratories), and the ﬁnal data
were obtained and analyzed via the Bio-Plex 3D Suspension
array system (Bio-Rad Laboratories). In addition to the
loading volume, the results were normalized for cell plating
number and total protein.
Immunohistochemistry
Parafﬁn-embedded whole-fat sections from UC and
control patients (n ¼ 4) were mounted on slides. The SP
staining was detected using an anti-SP rabbit polyclonal
antibody (AB1566; Millipore, Darmstadt, Germany) and the
EnVisionþ System HRP labeled Polymer Anti-Rabbit kit
(DAKO, Carpinteria, CA). The staining was performed at the
Translational Pathology Core, University of California at Los
Angeles, following a standard procedure described in Mil-
lipore’s manual for the primary antibody treatment (1:100
Ab dilution, pretreatment with citrate pH 6.0, antigen
retrieval).
Determination of Endotoxin Levels
Aliquots from the SP preparations used in our treat-
ments were diluted in cultured media as described earlier to
match the concentration and conditions represented in our
study. The Pierce LAL Chromogenic Endotoxin Quantiﬁca-
tion kit (Thermo Scientiﬁc, Rockford, IL) was used for the
quantitative measurement of endotoxin levels using
Escherichia coli 0111-B4 endotoxin as the standard. The
endotoxin measurements in all treatment preparations were
below detection levels (data not shown).
Statistical Analysis
The results were analyzed using the Prism professional
statistics software program (GraphPad Software, San Diego,
CA). Analyses of variances (ANOVA, one-way) as well as
Figure 1. Preadipocytes isolated from Crohn’s disease patients demonstrate different patterns of cytokine release
compared with cells isolated from healthy controls (n [ 4–11). Mesenteric preadipocytes were isolated from control ul-
cerative colitis (UC) and Crohn’s disease (CD) patients and conditioned media were collected at the third passage. Multiplex
analysis of a 27 human cytokine-containing panel revealed that preadipocytes isolated from CD patients secrete higher levels
of (A) IL-1b, (B) IL-9, and (F) IL-17 while the levels of (C) IL-10, (D) IL-12, and (E) IL-13 were signiﬁcantly lower compared with
the controls (C). In preadipocytes from UC patients, strong trends toward an increase were observed for (A) IL-1b and sig-
niﬁcant increases in (F) IL-17 compared with controls. *P < .05, **P < .01, ***P < .001, and #P < .1.
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were used for intergroup comparisons. P < .05 was
considered statistically signiﬁcant.
Results
Human Mesenteric Preadipocytes Isolated From
Crohn’s Disease Patients Demonstrate Distinct
Mediator Release Compared With Controls
We have isolated preadipocytes from mesenteric fat
depots of 10 control, 11 UC, and 11 Crohn’s disease patients
and expanded them in culture without prior freezing or
external stimulation. At the end of the second passage, fresh
medium was added to preadipocytes and collected after
8 hours for multiplex cytokine analysis. Analysis of the 27
cytokines showed changes in the release of mediators from
human preadipocytes during IBD compared with the con-
trols (Figure 1A–F). Preadipocytes isolated from Crohn’s
disease patients demonstrated statistically signiﬁcant in-
creases in the release of IL-1b, IL-9, and IL-17 (Figure 1A, B,
and F) and signiﬁcant decreases in the release of IL-10, IL-
12 (trend in Crohn’s disease), and IL-13 (Figure 1C–E)
compared with the controls. Of the 27 mediators included in
our panel, none exhibited differential secretion in pre-
adipocytes from UC patients compared with the controls;
only IL-1b and IL-17 were increased (strong trend for IL-1b,
P ¼ .07), and substantial differences were observed be-
tween preadipocytes isolated from UC and Crohn’s diseasepatients (IL-9, IL-10, IL-12, IL-13, and b-FGF, data not
shown), suggesting disease-dependent changes in these
cells. Patients for whom the cytokine values fell outside the
standard curve were excluded.
Human Mesenteric Preadipocytes From
Ulcerative Colitis Patients Express Higher Levels
of Tac1 Compared With Cells Isolated From
Control and Crohn’s Disease Patients
SP levels are modulated in the intestine during IBD.35,36
However, there is no information about whether human
preadipocytes express Tac-1 mRNA, the gene encoding for
SP. To address this, we isolated RNA from preadipocytes
from 11 control, 10 UC, and 11 Crohn’s disease patients and
examined the mRNA expression levels of Tac1 mRNA. We
found that human mesenteric preadipocytes express Tac1
mRNA. We also found increased mRNA levels of Tac1
in preadipocytes isolated from UC patients (Figure 2A,
P < .05, n ¼ 9–11, extreme outliers were determined using
the Grubbs test) compared with the control cells. There was
no statistically signiﬁcant difference (or trend) in Tac1
mRNA levels between preadipocytes from Crohn’s disease
and control patients. To verify the SP expression levels be-
tween control, UC, and Crohn’s disease patients, we per-
formed immunohistochemical analysis in whole-fat tissue
isolated from these patients using an anti-SP antibody, and
we observed increased expression of SP-positive cells in UC
Figure 2. Regulation of SP and its receptors NK-1R and NK-2R during inﬂammatory bowel disease. Human mesenteric
preadipocytes were isolated from control (C), ulcerative colitis (UC), and Crohn’s disease (CD) patients and cultured until the
third passage when the total RNA and protein were collected. (A) Real-time polymerase chain reaction analysis shows that
Tac1 (SP mRNA precursor) mRNA levels increase in human mesenteric preadipocytes during UC but not during CD. Similar
observations were made at the mRNA level for both (B) Tacr-1 and (C) Tacr-2 receptors (trend in UC). (D) Western blot analysis
shows that NK-1R protein levels increase during UC (trend) and CD in human preadipocytes while (E) immunohistochemical
staining with anti-SP antibody demonstrated an increased number of SP positive cells in whole mesenteric fat depots of UC
and CD patients compared with controls. *P < .05, **P < .01, and #P < .1.
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patient sections (Figure 2E).NK-1R and NK-2R mRNA Expression Is
Increased in Human Mesenteric Preadipocytes
From Inﬂammatory Bowel Disease Patients
We examined the expression levels of NK receptors in
preadipocytes of control, UC, and Crohn’s disease patients.
Densitometric analysis of Western immunoblots demon-
strated that Tacr-1 protein levels were increased in human
mesenteric preadipocytes isolated from Crohn’s disease
patients, and there was a strong trend for increase in UC
patient preadipocytes (Figure 2D, P < .05, n ¼ 4). At the
mRNA level, human preadipocytes isolated from UC and
Crohn’s disease patients expressed higher levels of the Tacr-
1 receptor compared with the controls (Figure 2B, P < .05
and P < .01 for UC and Crohn’s disease, respectively,
n ¼ 10–11, one extreme outlier was determined via Grubbs
test). The levels of Tacr-2 were statistically signiﬁcantlyhigher in the preadipocytes from Crohn’s disease patients
(Figure 2C, P < .05, n ¼ 10–11) compared with the controls,
although a trend for increased expression in the pre-
adipocytes from UC patients was evident.
Substance P Induces Inﬂammation-Associated
Cytokine mRNA Expression in Human Mesenteric
Preadipocytes Isolated From Inﬂammatory Bowel
Disease Patients
Previous studies from our group have demonstrated the
ability of SP to induce inﬂammation-associated responses in
preadipocytes and inﬂuence the metabolic responses of
mice via the activation of intracellular signaling pathways in
fat tissue.30,32 Here we exposed human mesenteric pre-
adipocytes from control, UC, and Crohn’s disease patients
to SP and examined their individual responses in the pro-
duction of cytokines that may affect IBD pathophysiology.
We observed that in preadipocytes from UC patients, SP
increased the mRNA expression of IL-1b, IL-12B, regulated
Figure 3. Substance P (SP) mediates cytokine mRNA expression from human mesenteric preadipocytes isolated from
inﬂammatory bowel disease (IBD) patients. Human mesenteric preadipocytes were isolated from control and IBD patients
and treated with SP for 8 hours. The total RNA was collected, and the cytokine mRNA levels were determined using real-time
polymerase chain reaction. (A) SP decreased cytokine mRNA levels in mesenteric preadipocytes from control patients (C) and
both (B) increased and (C) decreased cytokine expression in preadipocytes from ulcerative colitis (UC) patients. Preadipocytes
isolated from Crohn’s disease (CD) patients also demonstrated both (D) increased and (E) decreased cytokine mRNA
expression after SP treatment. Despite the similarities in the responses to SP between the UC and Crohn’s disease patient
preadipocytes, they also demonstrated disease-dependent responses. Values are expressed as fold changes from untreated.
*P < .05, **P < .01, and #P < .1.
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(RANTES), IL-17A, IL-15, vascular endothelial growth factor
A (VEGFA), platelet-derived growth factor subunit A
(PDGFA), interferon g (IFNg), chemokine (C–X–C motif)
ligand 9 (CXCL9), and monocyte chemotactic protein 1
(MCP-1) (Figure 3B) whereas the expression of CXCL10 and
IL-4 was signiﬁcantly decreased (Figure 3C, P < .05, n ¼ 8).
In preadipocytes isolated from Crohn’s disease patients, SP
treatment increased IL-12A, IL-17A, and CXCL10 mRNA
levels (Figure 3D, n ¼ 7) and decreased IL-4 and trans-
forming growth factor b mRNA levels (Figure 3E, n ¼ 7). In
the control patient preadipocytes, IL-2, RANTES, and
leukotriene B (LTB) mRNA expression (Figure 3A, n ¼ 10)
was reduced in response to SP treatment.Substance P Induces Differential Inﬂammatory
Bowel Disease–Dependent Cytokine mRNA
Expression in Human Mesenteric Preadipocytes
We next investigated whether the higher NK receptor
levels in IBD patient preadipocytes (Figure 2) reﬂect alteredresponsiveness to SP. Thus, we compared the fold difference
changes in cytokine mRNA expression in isolated pre-
adipocytes from control and IBD patients to examine
whether their responsiveness to SP is signiﬁcantly altered in
IBD. We observed that several cytokines responded in a
disease-dependent manner. The vast majority of responses
demonstrated higher fold changes in cytokine expression in
preadipocytes isolated from IBD patients compared with the
controls. More speciﬁcally, we show ﬁve mediators that
increase in response to SP only in preadipocytes isolated
from UC patients (Figure 4A, P < .05 for IL-2, and IL-15; P <
.01 for IL-17, VEGFA, and RANTES; and IL-17 also has a
strong trend toward increased expression in Crohn’s disease
patients, P < .1, n ¼ 7–8), three mediators that are
increased only in preadipocytes from Crohn’s disease pa-
tients (Figure 4A, P < .05 for LTB; P < .01 for IL-12A and
CXCL10, and all mediators also show a trend for increase in
UC, P < .1, n ¼ 7–8), whereas for IL-12B, MCP-1, and CXCL9
we only observed a strong trend for increase in UC patient
preadipocyte RNA (P < .1, n ¼ 7–8). A mini–heat-map
describing these changes in response to SP treatment
Figure 4. Human mesenteric preadipocytes isolated from inﬂammatory bowel disease (IBD) patients demonstrate
increased responsiveness in cytokine mRNA expression compared with preadipocytes isolated from control patients.
Mesenteric preadipocytes were isolated from control and IBD patients and exposed to substance P (SP) for 8 hours. Cytokine
mRNA was measured using multiplex FlrxScript panels (42-plex), and the fold change in response to SP treatment was
calculated for control (C), ulcerative colitis (UC), and Crohn’s disease (CD) patient-derived preadipocytes. (A) SP treatment of
UC and/or CD patient preadipocytes signiﬁcantly increases the mRNA expression of IL-2, IL-12A, IL-12B, IL-15, IL-17A, VEGF,
RANTES, MCP-1, CXCL9, CXCL10, and LTB compared with SP-treated preadipocytes from control patients. (B) Heat map
depicting the changes in cytokine mRNA expression in SP-treated IBD and control patient preadipocytes. *P < .05, **P < .01,
and #P < .1.
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provided and includes the strong trends toward change
(Figure 4B).Substance P Induces Inﬂammation-Associated
Cytokine Release in Human Mesenteric
Preadipocytes Isolated From Inﬂammatory Bowel
Disease Patients
At the protein level, in preadipocytes isolated from UC
patients the SP treatment induced the release of IL-2, IL-17A,
RANTES, PDGF-BB, macrophage inﬂammatory protein 1b
(MIP-1b), and colony-stimulating factor 2 (CSF-2) (Figure 5B,
n ¼ 7) and inhibited the release of IL-6, IL-12p70, IL-13,VEGF, and eotaxin (Figure 5C, n ¼ 7). Moreover, in Crohn’s
disease preadipocytes, SP induced the release of IL-1b, IL-2,
IL-15, IL-17A, basic ﬁbroblast growth factor (b-FGF), and
MIP-1b (Figure 5D, n ¼ 7) and inhibited the release of IL-7,
IL-8, IL-10, IL-12p70, IL-13, and MIP-1a (Figure 5E, n ¼ 7).
Treatment of preadipocytes isolated from control patients
with SP produced milder responses at both the mRNA and
protein secreted levels. In preadipocytes isolated from con-
trol patients, IL-2, IL-17A, tumor necrosis factor a (TNFa),
and IFNg release (Figure 5A, n ¼ 10) were reduced after SP
treatment. These results indicate that mesenteric pre-
adipocytes from Crohn’s disease, UC, and control patients
respond to SP by releasing different proinﬂammatory cyto-
kines at the mRNA and protein level.
Figure 5. Human mesenteric preadipocytes from control and inﬂammatory bowel disease patients demonstrate
different patterns of cytokine release in response to substance P (SP) treatment. Conditioned media were isolated from
human mesenteric preadipocytes treated with SP. (A) In media from control patients, SP treatment decreased (strong trends)
the release of cytokines from mesenteric preadipocytes. In media isolated from ulcerative colitis (UC) patients, SP both (B)
promotes and (C) inhibits the release of cytokines from preadipocytes. In media isolated from Crohn’s disease (CD) patients,
SP also (D) induces the release of several inﬂammation-associated cytokines and (E) inhibits the release of a number of cy-
tokines from mesenteric preadipocytes. The patterns of cytokine release between the conditioned media of UC and CD
patients demonstrate similarities (IL-2, IL-17A, MIP-1b) but also differences, suggesting disease-speciﬁc contributions of
preadipocytes in the course of these pathologic conditions. *P < .05, and #P < .1.
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Signiﬁcantly in Human Mesenteric Preadipocytes
From Inﬂammatory Bowel Disease Patients
Compared With Controls
We further analyzed the data included in Figure 5 to
signify the potential disease-based differences in SP respon-
siveness at the protein level. Of the 27 cytokines tested in
supernatants from SP-exposed UC and Crohn’s disease pre-
adipocytes, six cytokines showed statistically signiﬁcantly
increased secretion in both UC and Crohn’s disease
(Figure 6A, IL-1b, IL-2, IL-15, IL-17A, b-FGF, and MIP-1b, n¼
7–11), and four showed an increased release or a trend
toward increased release only in UC (Figure 6A, RANTES,
PDGF-BB, TNF-a, and CSF-2, n ¼ 7–11). Secretion of IL-13
and eotaxin in the supernatants of SP-exposed preadipocytes
was either signiﬁcantly decreased or had a trend toward sig-
niﬁcant decrease in both UC and Crohn’s disease (Figure 6A,
n ¼ 7–11) compared with the controls. IL-12 was statistically
signiﬁcantly decreased in SP-treated UC preadipocytes
(Figure 6A, n ¼ 7–11), whereas IL-8 and IL-10 (Figure 6A,
P < .05) were statistically signiﬁcantly decreased in Crohn’sdisease preadipocytes after SP treatment, compared with
the controls. A mini–heat-map depicting these changes in
response to SP treatment (including the strong trends toward
change, P < .1) is also provided (Figure 6B).
A modiﬁed Venn diagram (Figure 7) was created to
summarize the mRNA and protein responses of pre-
adipocytes from UC and Crohn’s disease patients compared
with the control patients to SP exposure and to highlight the
similarities and differences between the two diseases. IL-
17A was the sole mediator among 24 common molecules
(between mRNA and protein panels used) that was
increased after SP exposure of Crohn’s disease and UC
preadipocytes both in the mRNA and protein panels.
Preadipocytes Express Increased Interleukin-17A
mRNA During Inﬂammatory Bowel Disease
Whereas Interleukin-17 Receptor A mRNA Levels
Are Increased in Colonic Biopsies of
Inﬂammatory Bowel Disease Patients
Based on the proximity of mesenteric fat and the
inﬂamed intestine during IBD, adipocyte-derived products
Figure 6. Human mesenteric preadipocytes isolated from inﬂammatory bowel disease patients demonstrate increased
responsiveness in cytokine release compared with preadipocytes isolated from control patients. Mesenteric pre-
adipocytes were isolated and cultured; the conditioned media were isolated after SP treatment, and the cytokines were
measured using a multiplex magnetic assay kit (27-plex). (A) Substance P (SP) treatment induces a statistically signiﬁcantly
higher fold release of IL-1b, IL-2, IL-15, IL-17A, RANTES, PDGF-BB, b-FGF, TNFa (down-regulated in control), MIP-1b, and
CSF-2 and signiﬁcantly inhibits fold release of IL-8, IL-10, IL-12p70, IL-13, and eotaxin in preadipocytes isolated from ul-
cerative colitis (UC) and/or Crohn’s disease patients compared with control (C) patients. (B) Heat map depicting the changes in
cytokine release from SP-treated IBD and control patient preadipocytes. *P < .05, **P < .01, and #P < .1.
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Moreover, our results showed that IL-17A is the only
mediator modulated consistently after SP stimulation at
both the mRNA and protein levels in both Crohn’s disease
and UC preadipocytes. As also shown in Figure 1F, mesen-
teric preadipocytes from IBD patients produce higher IL-17
protein levels even in the absence of SP stimulation. To
investigate whether this change may potentially be impor-
tant in the regulation of responses in the intestine during
IBD, we examined the presence of IL-17 receptors in human
colonocytes and compared their levels in colonic biopsy
samples of IBD and control patients.
We ﬁrst veriﬁed that IL-17RA (the high-afﬁnity receptor
for IL-17A) is expressed in signiﬁcant amounts in NCM460human colonic epithelial cells (data not shown). Further-
more, we examined the IL-17RA expression levels in colonic
biopsy samples of control and IBD patients. We analyzed 19
non-IBD, 23 UC, and 30 Crohn’s disease colonic biopsy
samples, and we observed that IL-17RA is increased in bi-
opsy samples from UC and Crohn’s disease patients
compared with the control samples (Figure 8, P ¼ .0693 and
P < .05, respectively). Expression levels of IL-17RA are
shown separately for each patient, and the mean of the
control samples was used as a cutoff value to signify high
expression levels. Seven of 19 (36.84%) controls, 14 of 23
(60.86%) UC patients, and 19 of 30 (63.33%) Crohn’s dis-
ease patients were above that cutoff value, signifying
increased IL-17RA mRNA levels during IBD.
Figure 7. A Venn diagram summarizes the mRNA and
protein responses of preadipocytes from ulcerative colitis
(UC) and Crohn’s disease (CD) patients compared with
control patients to substance P (SP) exposure and high-
lights the similarities and differences between the two
diseases. IL-17A is depicted as the mediator demonstrating
the most consistent responses (both in Crohn’s disease and
UC and at both the mRNA and protein levels) to SP treatment
in preadipocytes from inﬂammatory bowel disease compared
with control patients.
Figure 8. Increased interleukin 17 receptor (IL-17R) mRNA
expression in human colonic biopsy samples during in-
ﬂammatory bowel disease. Colonic biopsy samples were
obtained from patients during colonoscopy and total RNA
was isolated. Real-time polymerase chain reaction shows
elevated IL-17RA mRNA levels in ulcerative colitis (UC)
and Crohn’s disease (CD) biopsy samples compared with
controls (C).
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We found that mesenteric preadipocytes from control
and IBD patients demonstrated differential mediator
secretion patterns even after days in culture (Figure 1). Our
results also indicate that SP exerts potent anti-inﬂammatory
effects in preadipocytes from control patients compared
with the mainly proinﬂammatory stimulation in cells from
patients with IBD. This stark discrepancy indicates that
components of the mesenteric fat depots have acquired
disease-dependent characteristics, adding to the complexity
of the factors that may contribute to the pathophysiology.
Most importantly, our results (Figure 2) demonstrate that
human mesenteric preadipocytes express Tac1 mRNA as
well as both NK-1 and NK-2 receptors.
Our ﬁndings also show that preadipocytes isolated from
IBD patients respond to SP in a considerably different
manner from the controls, with profound differences in the
responses between preadipocytes isolated from UC and
Crohn’s disease patients (Figures 3 and 5) possibly due to
intrinsic characteristics these cells acquired during the
course of IBD. Further analysis lead to the identiﬁcation of an
IBD-speciﬁc cytokine response pattern after exposure to SP
(Figures 4 and 6). Overall, and despite the variability in pa-
tient backgrounds and potential treatments, we observed
signiﬁcant and quite consistent differences in the inherent
ability of preadipocytes from patients from different disease
groups to respond to SP. These responses can be proin-
ﬂammatory and anti-inﬂammatory (at both the transcriptionand secretion levels), suggesting the potential involvement of
mesenteric adipose tissue in disease manifestations and ac-
tivity in the different phases of colitis.
We have shown that NK-1R is present in mouse
mesenteric adipose tissue and that its expression is regu-
lated during colitis.30 However, this is the ﬁrst evidence
that expression of NK-1R is regulated differentially by IBD
in preadipocytes, leading to speciﬁc inﬂammatory SP re-
sponses for UC or Crohn’s disease. Previous observations
suggested a possible role of creeping fat in the pathophys-
iology of Crohn’s disease alone; however, ours is the ﬁrst
evidence that mesenteric adipose tissue may be involved in
the pathophysiology of UC as well. This is an important
observation because only Crohn’s disease (and not UC)
is associated with a creeping fat phenotype, suggesting
different mechanisms for mesenteric fat activation in the
two disease sates. Increased Tacr-1mRNA expression in IBD
preadipocytes likely involves activation of nuclear factor kB
(NF-kB) and binding of this transcription factor to sites at
the promoter region of Tacr-1, shown to be important for its
transcription.37 SP alone can also increase transcription of
Tacr-1 in control mesenteric preadipocytes, as we previ-
ously showed elsewhere.30
The diverse differential responses described here in hu-
man mesenteric preadipocytes in response to SP during IBD
are both proinﬂammatory and anti-inﬂammatory. Many of
these molecules have been implicated in IBD pathophysi-
ology, and their levels depend on disease activity and/or
different cell populations involved in this group of diseases.
For example, IL-1b polymorphisms are linked with IBD dis-
ease activity and phenotype, and IL-1b levels are elevated in
serum and colonic biopsy samples of IBD and non-IBD colitis
patients.38 IL-12 and IL-15 are highly expressed in IBD, and
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Antibodies against the p40 subunit of IL-12/23 are
currently in clinical trials for IBD treatment.41 IL-8 is
increased in colonic intestinal epithelium in IBD and is a
potent neutrophil attractant.42 IL-2 polymorphisms seem to
predispose to UC, and knockout animals for IL-2 or IL-10 are
known to develop colitis.43,44 IL-13 seems to have a protec-
tive role against colitis, and its levels are decreased in IBD
colon biopsy samples of pediatric UC patients.45,46 VEGF is
also considered a susceptibility factor for IBD, linking
angiogenesis with the development of colitis.47 Biologic fac-
tors targeting TNFa are the most widely used and effective
treatment for IBD currently.48 Several of the cytokines
demonstrating IBD-dependent responses to SP treatment in
our study—eotaxin,49 PDGF-BB, b-FGF,50 CXCL9,51 CXCL-
10,52 MIP-1b (CCL4),53 RANTES (CCL5),54 MCP-1 (CCL2),30
CSF-2 (GM-CSF),55,56 and LTB57—have been implicated in
IBD pathophysiology. Collectively, the multitude of respon-
sive mediators to SP in mesenteric preadipocytes from IBD
patients highlights the potential magnitude of the involve-
ment ofmesenteric preadipocytes in IBD pathophysiology via
regulation of inﬂammatory responses that may affect the
involved intestine.
Mediators described here to be affected by SP treatment
in human mesenteric preadipocytes from both UC and
Crohn’s disease patients have been implicated in the regu-
lation of innate and adaptive immunity. In addition to their
similarities, the combination of affected mediators by SP
is mainly reminiscent of changes in macrophage responses
in UC (IL-1b, IL-12, IL-15, CXCL10, GM-CSF, RANTES, MIP-1,
IFNg) and mostly resemble dendritic cell changes observed
in Crohn’s disease (IL-1b, IL-2, IL-12, IL-15, CXCL10, MIP-1)
patient preadipocytes.58,59 In both these cases, the
described changes in response to SP can affect T-cell func-
tion (via IFNg, IL-10, and IL4).60,61
Interestingly, a considerable number of SP-induced me-
diators in preadipocytes isolated from both UC and Crohn’s
disease patients (IL-1b, IL-12, IL-13, CCL2, CCL4) described
here are downstream targets of IL-17A activation in mac-
rophages, T helper cells, and intestinal epithelial cells.62
Collectively, treatment of human preadipocytes isolated
from UC and Crohn’s disease patients with SP leads to the
generation of responses that may be linked to inﬂammation,
cellular development and proliferation, tissue development,
connective tissue development and function, and hemato-
logic tissue development and function, showing the poten-
tial involvement of SP and its signaling on preadipocytes on
several aspects of IBD pathophysiology.
It is important to note that of all the inﬂammatory me-
diators that we were able to screen through in this study,
IL-17A was the only one that exhibited consistent IBD-
associated changes in mRNA expression and protein secre-
tion levels in preadipocytes in response to SP treatment
(schematically described in Figure 7) after SP stimulation
compared with the controls. Previous studies indicated that
IL-17 is regulated by SP in intestinal inﬂammatory T cells,63
whereas an IL-23R haplotype, involved in the induction of
IL-17A expression, is a risk factor for IBD.5 Moreover, IL-17
levels are increased in colonic biopsy samples from UC andCrohn’s disease patients.64 Here, we present evidence that
human mesenteric preadipocytes are a novel source of IL-
17A, with higher expression during UC and Crohn’s dis-
ease. In addition, human mesenteric preadipocytes from IBD
patients have elevated NK-1R receptors and demonstrate
increased expression and secretion of IL-17 in response to
SP, and its receptor, IL-17RA, shows increased levels in
colonic biopsy samples of IBD patients (Figure 8). Under-
standably, fat may not be the only source of IL-17 during
colitis and may not reﬂect the cause behind the changes
observed in the expression of IL-17RA in the gut during IBD.
However, fat represents a novel reserve of IL-17 during the
disease and may affect the progress of IBD by altering in-
testinal responses via interactions with IL-17RA.
This observation along with the identiﬁcation of IL-17 as
the most consistently regulated mediator in human
mesenteric preadipocytes isolated from IBD patients in
response to SP suggests a potential role for this neuropep-
tide in the regulation of inﬂammatory changes in the in-
testine during IBD (both UC and Crohn’s disease) via
modulation of IL-17 expression in the adjacent mesenteric
preadipocytes. Furthermore, our observations introduce the
preadipocytes as a novel cellular population with immune
properties that are likely involved in the regulation of in-
testinal inﬂammation during IBD.References
1. Chang MM, Leeman SE. Isolation of a sialogogic peptide
from bovine hypothalamic tissue and its characterization
as substance P. J Biol Chem 1970;245:4784–4790.
2. Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachy-
kinins and their receptors: contributions to physiological
control and the mechanisms of disease. Physiol Rev
2014;94:265–301.
3. Koon HW, Pothoulakis C. Immunomodulatory properties
of substance P. Ann NY Acad Sci 2006;1088:23–40.
4. Koon HW, Pothoulakis C. Immunomodulatory properties
of substance P: the gastrointestinal system as a model.
Ann NY Acad Sci 2006;1088:23–40.
5. Kaser A, Zeissig S, Blumberg RS. Inﬂammatory bowel
disease. Annu Rev Immunol 2010;28:573–621.
6. Gross KJ, Pothoulakis C. Role of neuropeptides in in-
ﬂammatory bowel disease. Inﬂamm Bowel Dis 2007;
13:918–932.
7. Mantyh CR, Vigna SR, Bollinger RR, et al. Differential
expression of substance P receptors in patients with
Crohn’s disease and ulcerative colitis. Gastroenterology
1995;109:850–860.
8. Ottaway CA. Role of the neuroendocrine system in
cytokine pathways in inﬂammatory bowel disease.
Aliment Pharmacol Ther 1996;10(Suppl 2):10–15.
9. Pothoulakis C, Castagliuolo I, Leeman SE, et al. Sub-
stance P receptor expression in intestinal epithelium in
clostridium difﬁcile toxin A enteritis in rats. Am J Physiol
1998;275:G68–G75.
10. Renzi D, Pellegrini B, Tonelli F, et al. Substance P (neu-
rokinin-1) and neurokinin A (neurokinin-2) receptor gene
and protein expression in the healthy and inﬂamed hu-
man intestine. Am J Pathol 2000;157:1511–1522.
July 2015 SP, Adipocytes, and IBD 43111. Mantyh CR, Vigna SR, Maggio JE, et al. Substance P
binding sites on intestinal lymphoid aggregates and
blood vessels in inﬂammatory bowel disease correspond
to authentic NK-1 receptors. Neurosci Lett 1994;
178:255–259.
12. Castagliuolo I, Riegler M, Pasha A, et al. Neurokinin-1
(NK-1) receptor is required in Clostridium difﬁcile–in-
duced enteritis. J Clin Invest 1998;101:1547–1550.
13. Castagliuolo I, Morteau O, Keates AC, et al. Protective
effects of neurokinin-1 receptor during colitis in mice:
role of the epidermal growth factor receptor. Br J Phar-
macol 2002;136:271–279.
14. Koon HW, Zhao D, Zhan Y, et al. Substance P mediates
antiapoptotic responses in human colonocytes by Akt
activation. Proc Natl Acad Sci USA 2007;104:2013–2018.
15. Pothoulakis C, Castagliuolo I, LaMont JT, et al. CP-96,
345, a substance P antagonist, inhibits rat intestinal re-
sponses to Clostridium difﬁcile toxin A but not cholera
toxin. Proc Natl Acad Sci USA 1994;91:947–951.
16. Stucchi AF, Shofer S, Leeman S, et al. NK-1 antagonist
reduces colonic inﬂammation and oxidative stress in
dextran sulfate-induced colitis in rats. Am J Physiol
Gastrointest Liver Physiol 2000;279:G1298–G1306.
17. Weinstock JV, Blum A, Metwali A, et al. Substance P
regulates Th1-type colitis in IL-10 knockout mice.
J Immunol 2003;171:3762–3767.
18. Di Sebastiano P, Grossi L, Di Mola FF, et al. SR140333, a
substance P receptor antagonist, inﬂuences morpho-
logical and motor changes in rat experimental colitis. Dig
Dis Sci 1999;44:439–444.
19. Koon HW, Zhao D, Na X, et al. Metalloproteinases and
transforming growth factor-alpha mediate substance P-
induced mitogen-activated protein kinase activation and
proliferation in human colonocytes. J Biol Chem 2004;
279:45519–45527.
20. Castagliuolo I, Valenick L, Liu J, Pothoulakis C.
Epidermal growth factor receptor transactivation medi-
ates substance P-induced mitogenic responses in U-373
MG cells. J Biol Chem 2000;275:26545–26550.
21. GoodeT,O’Connell J, AntonP, et al.Neurokinin-1 receptor
expression in inﬂammatory bowel disease: molecular
quantitation and localisation. Gut 2000;47:387–396.
22. Castagliuolo I, Keates AC, Qiu B, et al. Increased sub-
stance P responses in dorsal root ganglia and intestinal
macrophages during Clostridium difﬁcile toxin A enteritis
in rats. Proc Natl Acad Sci USA 1997;94:4788–4793.
23. Lieb K, Fiebich BL, Berger M, et al. The neuropeptide
substance P activates transcription factor NF-kappa B
and kappa B-dependent gene expression in human as-
trocytoma cells. J Immunol 1997;159:4952–4958.
24. Zhao D, Kuhnt-Moore S, Zeng H, et al. Substance P-
stimulated interleukin-8 expression in human colonic
epithelial cells involves Rho family small GTPases. Bio-
chem J 2002;368:665–672.
25. Blain A, Cattan S, Beaugerie L, et al. Crohn’s disease
clinical course and severity in obese patients. Clin Nutr
2002;21:51–57.
26. Desreumaux P, Ernst O, Geboes K, et al. Inﬂammatory
alterations in mesenteric adipose tissue in Crohn’s dis-
ease. Gastroenterology 1999;117:73–81.27. Herlinger H, Furth EE, Rubesin SE. Fibrofatty proliferation
of the mesentery in Crohn disease. Abdom Imaging
1998;23:446–448.
28. Karmiris K, Koutroubakis IE, Xidakis C, et al. Circulating
levels of leptin, adiponectin, resistin, and ghrelin in in-
ﬂammatory bowel disease. Inﬂamm Bowel Dis 2006;
12:100–105.
29. Tchkonia T, Thomou T, Zhu Y, et al. Mechanisms and
metabolic implications of regional differences among fat
depots. Cell Metab 2013;17:644–656.
30. Karagiannides I, Kokkotou E, Tansky M, et al. Induction
of colitis causes inﬂammatory responses in fat depots:
evidence for substance P pathways in human mesenteric
preadipocytes. Proc Natl Acad Sci USA 2006;103:
5207–5212.
31. Gross K, Karagiannides I, Thomou T, et al. Substance P
promotes expansion of human mesenteric preadipocytes
through proliferative and antiapoptotic pathways. Am J
PhysiolGastrointest Liver Physiol 2009;296:G1012–G1019.
32. Karagiannides I, Bakirtzi K, Kokkotou E, et al. Role of
substance P in the regulation of glucose metabolism via
insulin signaling-associated pathways. Endocrinology
2011;152:4571–4580.
33. Karagiannides I, Stavrakis D, Bakirtzi K, et al. Substance
P (SP)-neurokinin-1 receptor (NK-1R) alters adipose tis-
sue responses to high-fat diet and insulin action. Endo-
crinology 2011;152:2197–2205.
34. Tchkonia T, Giorgadze N, Pirtskhalava T, et al. Fat depot
origin affects adipogenesis in primary cultured and
cloned human preadipocytes. Am J Physiol Regul Integr
Comp Physiol 2002;282:R1286–R1296.
35. Bernstein CN, Robert ME, Eysselein VE. Rectal sub-
stance P concentrations are increased in ulcerative co-
litis but not in Crohn’s disease. Am J Gastroenterol 1993;
88:908–913.
36. Mazumdar S, Das KM. Immunocytochemical localization
of vasoactive intestinal peptide and substance P in the
colon from normal subjects and patients with inﬂamma-
tory bowel disease. Am J Gastroenterol 1992;87:
176–181.
37. Simeonidis S, Castagliuolo I, Pan A, et al. Regulation of
the NK-1 receptor gene expression in human macro-
phage cells via an NF-kappa B site on its promoter. Proc
Natl Acad Sci USA 2003;100:2957–2962.
38. Coccia M, Harrison OJ, Schiering C, et al. IL-1bmediates
chronic intestinal inﬂammation by promoting the accu-
mulation of IL-17A secreting innate lymphoid cells and
CD4þ Th17 cells. J Exp Med 2012;209:1595–1609.
39. Liu ZJ, Geboes K, Colpaert S, et al. IL-15 is highly
expressed in inﬂammatory bowel disease and regulates
local T cell-dependent cytokine production. J Immunol
2000;164:3608–3615.
40. Schwartz D. Anti-IL-12/23: the next big thing in IBD?
Inﬂamm Bowel Dis 2009;15:1927–1928.
41. Reenaers C, Louis E, Belaiche J. Current directions of
biologic therapies in inﬂammatory bowel disease. Therap
Adv Gastroenterol 2010;3:99–106.
42. Daig R, Andus T, Aschenbrenner E, et al. Increased
interleukin 8 expression in the colon mucosa of patients
with inﬂammatory bowel disease. Gut 1996;38:216–222.
432 Sideri et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 443. Parkes M, Satsangi J, Jewell D. Contribution of the IL-2
and IL-10 genes to inﬂammatory bowel disease (IBD)
susceptibility. Clin Exp Immunol 1998;113:28–32.
44. Yarkoni S, Sagiv Y, Kaminitz A, Askenasy N. Interleukin 2
targeted therapy in inﬂammatory bowel disease. Gut
2009;58:1705–1706.
45. Kadivar K, Ruchelli ED, Markowitz JE, et al. Intestinal
interleukin-13 in pediatric inﬂammatory bowel disease
patients. Inﬂamm Bowel Dis 2004;10:593–598.
46. Kucharzik T, Lugering N, Weigelt H, et al. Immunoregu-
latory properties of IL-13 in patients with inﬂammatory
bowel disease; comparison with IL-4 and IL-10. Clin Exp
Immunol 1996;104:483–490.
47. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links
angiogenesis and inﬂammation in inﬂammatory bowel
disease pathogenesis. Gastroenterology 2009;
136:585–595 e585.
48. Peyrin-Biroulet L. Anti-TNF therapy in inﬂammatory
bowel diseases: a huge review. Minerva Gastroenterol
Dietol 2010;56:233–243.
49. Rehman MQ, Beal D, Liang Y, et al. B cells secrete
eotaxin-1 in human inﬂammatory bowel disease. Inﬂamm
Bowel Dis 2013;19:922–933.
50. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-
FGF, and TGF-beta in Crohn’s disease and ulcerative
colitis: a novel mechanism of chronic intestinal inﬂam-
mation. Am J Gastroenterol 2001;96:822–828.
51. Lacher M, Kappler R, Berkholz S, et al. Association of a
CXCL9 polymorphism with pediatric Crohn’s disease.
Biochem Biophys Res Commun 2007;363:701–707.
52. Singh UP, Singh S, Taub DD, Lillard JW Jr. Inhibition of
IFN-gamma-inducible protein-10 abrogates colitis in IL-
10/ mice. J Immunol 2003;171:1401–1406.
53. Banks C, Bateman A, Payne R, et al. Chemokine
expression in IBD. Mucosal chemokine expression is
unselectively increased in both ulcerative colitis and
Crohn’s disease. J Pathol 2003;199:28–35.
54. Ansari N, Abdulla J, Zayyani N, et al. Comparison of
RANTES expression in Crohn’s disease and ulcerative
colitis: an aid in the differential diagnosis? J Clin Pathol
2006;59:1066–1072.
55. Dabritz J, Bonkowski E, Chalk C, et al. Granulocyte
macrophage colony-stimulating factor auto-antibodies
and disease relapse in inﬂammatory bowel disease. Am
J Gastroenterol 2013;108:1901–1910.
56. Gathungu G, Kim MO, Ferguson JP, et al. Granulocyte-
macrophage colony-stimulating factor autoantibodies: a
marker of aggressive Crohn’s disease. Inﬂamm Bowel
Dis 2013;19:1671–1680.57. Agyekum S, Church A, Sohail M, et al. Expression of
lymphotoxin-beta (LT-beta) in chronic inﬂammatory
conditions. J Pathol 2003;199:115–121.
58. Lacey DC, Achuthan A, Fleetwood AJ, et al. Deﬁning
GM-CSF- and macrophage-CSF-dependent macro-
phage responses by in vitro models. J Immunol 2012;
188:5752–5765.
59. Arneja A, Johnson H, Gabrovsek L, et al. Qualitatively
different T cell phenotypic responses to IL-2 versus IL-15
are uniﬁed by identical dependences on receptor signal
strength and duration. J Immunol 2014;192:123–135.
60. Malek TR, Yu AX, Scibelli P, et al. Broad programming by
IL-2 receptor signaling for extended growth to multiple
cytokines and functional maturation of antigen-activated
T cells. J Immunol 2001;166:1675–1683.
61. Ni GY, Wang YJ, Wu XL, et al. Graphene oxide absorbed
anti-IL10R antibodies enhance LPS induced immune
responses in vitro and in vivo. Immunol Lett 2012;
148:126–132.
62. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of
interleukin-17A and -17F in host defense against
mucoepithelial bacterial infection and allergic responses.
Immunity 2009;30:108–119.
63. Beinborn M, Blum A, Hang L, et al. TGF-beta regulates T-
cell neurokinin-1 receptor internalization and function.
Proc Natl Acad Sci USA 2010;107:4293–4298.
64. Rovedatti L, Kudo T, Biancheri P, et al. Differential
regulation of interleukin 17 and interferon gamma pro-
duction in inﬂammatory bowel disease. Gut 2009;58:
1629–1636.Received November 17, 2014. Accepted March 12, 2015.
Correspondence
Address correspondence to: Charalabos Pothoulakis, MD, Inﬂammatory Bowel
Disease Center, Division of Digestive Diseases, David Geffen School of
Medicine at UCLA, MRL1240, 675 Charles E. Young Drive South, Los
Angeles, California 90095. e-mail: cpothoulakis@mednet.ucla.edu; fax: 310-
825-3542.
Acknowledgments
Dr Sarah Dry and the Translational Pathology Core Laboratory, Department
of Pathology, University of California at Los Angeles, for providing human
mesenteric fat tissue samples for our studies.
Conﬂicts of interest
The authors disclose no conﬂicts.
Funding
This study was funded by NIH NIDDK DK 47343 and DK60729 (to C.P.); K01
DK084256 (to W.H.K.); Research Fellowship Award from the Crohn’s Colitis
Foundation of America (I.K., K.B.); Research Grant from the Broad Medical
Foundation (to I.K.); the Neuroendocrine Assay Core and Project 2 supported
by P50 DK 64539 (to I.K., C.P.); United States Public Health Service grant
DK046763 (to D.Q.S.); R01DK68271 and P30CA14599 (to J.R.T.).
